Inhibition of CaMKII Does Not Attenuate Cardiac Hypertrophy in Mice with Dysfunctional Ryanodine Receptor by Chakraborty, Asima et al.
Inhibition of CaMKII Does Not Attenuate Cardiac
Hypertrophy in Mice with Dysfunctional Ryanodine
Receptor
Asima Chakraborty1.¤, Daniel A. Pasek1., Tai-Qin Huang1, Angela C. Gomez2, Naohiro Yamaguchi2,
Mark E. Anderson3, Gerhard Meissner1*
1 Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC, United States of America, 2 Department of Regenerative Medicine and Cell
Biology, Medical University of South Carolina, Charleston, SC, United States of America, 3 Division of Cardiovascular Medicine, Departments of Internal Medicine, and
Molecular Physiology and Biophysics, University of Iowa, Iowa City, IA, United States of America
Abstract
In cardiac muscle, the release of calcium ions from the sarcoplasmic reticulum through ryanodine receptor ion channels
(RyR2s) leads to muscle contraction. RyR2 is negatively regulated by calmodulin (CaM) and by phosphorylation of Ca2+/CaM-
dependent protein kinase II (CaMKII). Substitution of three amino acid residues in the CaM binding domain of RyR2 (RyR2-
W3587A/L3591D/F3603A, RyR2ADA) impairs inhibition of RyR2 by CaM and results in cardiac hypertrophy and early death of
mice carrying the RyR2ADA mutation. To test the cellular function of CaMKII in cardiac hypertrophy, mutant mice were
crossed with mice expressing the CaMKII inhibitory AC3-I peptide or the control AC3-C peptide in the myocardium.
Inhibition of CaMKII by AC3-I modestly reduced CaMKII-dependent phosphorylation of RyR2 at Ser-2815 and markedly
reduced CaMKII-dependent phosphorylation of SERCA2a regulatory subunit phospholamban at Thr-17. However the
average life span and heart-to-body weight ratio of Ryr2ADA/ADA mice expressing the inhibitory peptide were not altered
compared to control mice. In Ryr2ADA/ADA homozygous mice, AC3-I did not alter cardiac morphology, enhance cardiac
function, improve sarcoplasmic reticulum Ca2+ handling, or suppress the expression of genes implicated in cardiac
remodeling. The results suggest that CaMKII was not required for the rapid development of cardiac hypertrophy in
Ryr2ADA/ADA mice.
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Introduction
In cardiac muscle, excitation-contraction coupling in response
to an action potential initiates an influx of Ca2+ ions via
dihydropyridine-sensitive L-type Ca2+ channels (Cav1.2). This
triggers the massive release of Ca2+ from an intracellular Ca2+-
storage organelle, the sarcoplasmic reticulum (SR), by opening
type 2 ryanodine receptor ion channels (RyR2s) [1]. The released
Ca2+ causes muscle contraction. Sequestration of released Ca2+
back into the SR by an ATP-dependent Ca2+ pump (SERCA2a)
leads to muscle relaxation.
Ca2+/calmodulin-dependent protein kinase II (CaMKII) regu-
lates the cellular entry of activator Ca2+ through Cav1.2 and
thereby SR Ca2+ release via RyR2 [1–4]. Phosphorylation of
SERCA2a regulatory protein phospholamban (PLN) at Ser-16 by
protein kinase A and Thr-17 by CaMKII enhances SR Ca2+
sequestration [5]. Site directed mutagenesis of the predominant
CaMKII phosphorylation site of RyR2 to mimic constitutively
phosphorylated (RyR2-S2815D) and dephosphorylated (S2815A)
channels, showed that CaMKII-dependent phosphorylation of
RyR2 increases channel open probability and the risk of heart
failure in mice following transverse aortic constriction [6,7].
Cardiac myocytes express two major CaMKII isoforms, c and
d. Of these, CaMKIId has two splice variants, B and C.
CaMKIIdB has a nuclear localization signal and transcriptionally
regulates signaling pathways in cardiac myopathies [8–10].
Overexpression of CaMKIIdB or CaMKIIdC induced transactiva-
tion of myocyte enhancer factor 2 (MEF2)-dependent gene
expression and up-regulation of hypertrophic marker genes [11].
Overexpression of cytosolic CaMKIIdC increased RyR2 and PLN
phosphorylation, enhanced Ca2+ spark activity, and reduced SR
Ca2+ content [11,12]. CaMKIId knockout mice had no major
changes in ventricular structure and function [13,14]. However,
after pressure overload induced by transaortic banding surgery,
cardiac remodeling was reduced in CaMKIId deficient mice,
which exhibited inhibition of RyR2 phosphorylation and reduced
SR Ca2+ leak [13,14]. The results suggested that inhibition of
CaMKII may limit the development of heart failure.
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Based on the understanding of CaMKII as a pathological
signaling molecule in cardiomyopathies, we asked whether an
active strategy of chronic myocardial-targeted CaMKII inhibition
could prevent or reduce cardiac hypertrophy in a mouse model
(Ryr2ADA/ADA mice) with a well-defined mutation in RyR2.
Ryr2ADA/ADA mice have three substituted amino acid residues in
the calmodulin (CaM) binding domain of RyR2 (RyR2-W3587A/
L3591D/F3603A, RyR2ADA) that disrupt its CaM inhibition at
diastolic and systolic Ca2+ concentrations and result in cardiac
hypertrophy and the early death of RyR2ADA/ADA mice [15].
While wild-type and Ryr2ADA/ADA mice had comparable CaMKII
activities in 1-day old mice using an in vitro kinase assay [15],
these studies did not rule out an in vivo procardiomyopathic role
of CaMKII in Ryr2ADA/ADA mice. Additionally, in vitro measure-
ments of CaMKII activity do not necessarily reflect the cellular
activities in mice. Differences in Ca2+ handling due to CaM
impairment of RyR2 function and CaM distribution due to loss of
RyR2 CaM binding may result in altered CaMKII activity in
homozygous mutant hearts, which are difficult to assess in an in
vitro assay.
To determine whether CaMKII inhibition could prevent or
reduce cardiac hypertrophy, we crossed mutant mice with mice
transgenically expressing CaMKII autocamtide 3 inhibitory
peptide (AC3-I) or control peptide (AC3-C). Transgenic overex-
pression of AC3-I protected mouse hearts against pathological
remodeling in response to myocardial infarction and b-adrenergic
stimulation [16]. The present study shows that CaMKII inhibitory
peptide AC3-I reduced phosphorylation of PLN at Thr-17 in
Ryr2+/+ and Ryr2ADA/ADA mice without significantly altering life
span, cardiac morphology and performance, or markers of cardiac
hypertrophy relative to mice expressing the control peptide. The
findings suggest that the pathological effects of the RyR2ADA
mutation are independent of myocardial CaMKII.
Materials and Methods
Ethics Statement
This study was carried out in accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health. The protocol was approved by
the University of North Carolina at Chapel Hill Institutional
Animal Care and Use Committee (10-062).
Materials
[3H]Ryanodine was obtained from Perkin Elmer Life Sciences.
Protease and phosphatase inhibitor cocktails were from Sigma.
Rabbit polyclonal antibody F9221 against RyR2 amino acid
sequence 1372–1387 was produced by New England Peptide.
Rabbit polyclonal antibody pRyR2 on Ser-2809 (A010-30AP) was
from Badrilla (Leeds, UK). Rabbit polyclonal antibody to pRyR2
on Ser-2815 was the generous gift of Dr. Andrew Marks. Mouse
monoclonal antibody PLN (A010-14) and rabbit polyclonal
antibodies pPLN on Ser-16 (A010-12) and Thr-17 (A010-13)
were from Badrilla (Leeds, UK). Rabbit polyclonal antibody
pCaMKII on Thr-286 (ab32678) and two rabbit polyclonal
antibodies against the conserved N-terminal (ab136400) and C-
terminal (ab37999) regions of CaMKIIc and CaMKIId were from
Abcam. Comparable results were obtained using the two CaMKII
Figure 1. Survival of Ryr2 ADA/ADA/AC3-C and Ryr2ADA/ADA/AC3-I mice. Mean lifetimes 6 SEM of Ryr2ADA/ADA mice expressing CaMKII control AC3-
C and inhibitory AC3-I peptides were 26.461.6 (n = 16) and 28.163.0 (n = 16) days, respectively.
doi:10.1371/journal.pone.0104338.g001
Ryr2ADA/ADA Mice and AC3 Peptides
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antibodies. Rabbit polyclonal antibodies protein kinase D (PKD)
(#2052) and pPKD on S744/8 (#2054) and S916 (#2051) were
from Cell Signaling Technology. Chemicals were from Sigma-
Aldrich unless specified otherwise.
Genetically modified mice
Ryr2+/ADA mice [15] were mated with mice expressing the
CaMKII inhibitory AC3-I peptide or the control AC3-C peptide
[16]. Mice with AC3-I or AC3-C peptide expression were each
backcrossed at least 5 times to 129Svev genetic background. Nine
different genotypes of mice were obtained by crossing Ryr2+/ADA
mice expressing either of the two peptides according to Mendelian
Law. Of these, the 4 genotypes investigated were Ryr2+/+ mice
expressing AC3-I or AC3-C, and Ryr2ADA/ADA mice expressing
AC3-I or AC3-C.
Echocardiography
To determine left ventricular cardiac function, transthoracic M-
mode echocardiography was performed on restrained, unanesthe-
tized 10-day old mice, using the Vevo 2100 high resolution
imaging system (VisualSonics) with 40 MHz probe [15]. Mice
were restrained by taping down gently on a warmed board (Indus
Industries for VisualSonics).
Morphological analysis
Hearts from 9–11 day old mice were fixed with 4% (w/v)
paraformaldehyde in PBS (pH 7.4) and dehydrated using increas-
Figure 2. Echocardiograms of wild-type and mutant hearts. Representative M-mode echocardiograms of 10-day old Ryr2+/+/AC3-C (WC) and/
AC3-I (WI) and Ryr2ADA/ADA/AC3-C (HC) and/AC3-I (HI) mice are shown. Left ventricular end-diastolic (right arrows) and end-systolic (left arrows)
dimensions are indicated.
doi:10.1371/journal.pone.0104338.g002
Table 1. Echocardiography of 10-day old mice double targeted for RyR2ADA and AC3 peptides.
Parameters Ryr2
+/+ Ryr2+/+ Ryr2ADA/ADA Ryr2ADA/ADA
AC3-C AC3-I AC3-C AC3-I
(n = 8) (n = 6) (n = 8) (n = 6)
LV/BW 0.14260.010 0.15360.016 0.26760.034a 0.31260.042a
HR (bpm) 612626 613620 484614a 477618a
LVEDD (mm) 1.6360.10 1.5860.10 3.0160.27a 2.9360.19a
LVESD (mm) 0.5960.07 0.6560.11 2.5260.29a 2.3860.21a
FS (%) 64.363.4 59.466.1 17.562.2a 19.361.9a
IVSD (mm) 0.8460.07 0.8960.09 0.8060.04 0.7060.04
IVSS (mm) 1.2960.07 1.2960.13 1.0060.05a 0.9060.05a
LVPWD (mm) 0.7060.06 0.7260.05 0.9460.12 0.7860.07
LVPWS (mm) 1.0860.07 1.0960.07 1.1760.11 0.9960.09
EF(%) 92.862.4 89.962.1 38.164.3a 44.162.1a
LV/BV, left ventricular weight to body weight; HR, heart rate; bpm, beats/min; LVEDD, left ventricular end diastolic dimension; LVESD, left ventricular end systolic dimension; FS,
fractional shortening (LVEDD - LVESD)/LVEDD; IVSD, interventricular septum diastolic thickness; IVSS, interventricular septum systolic thickness; LVPWD, left ventricular posterior
wall diastolic thickness; LVPWS, left ventricular posterior wall systolic thickness, EF, ejection fraction. Data are the mean 6 SEM of number of mice shown in parenthesis.
ap,0.05 compared to Ryr2+/+/AC3-C and Ryr2+/+/AC3-I using one way ANOVA.
doi:10.1371/journal.pone.0104338.t001
Ryr2ADA/ADA Mice and AC3 Peptides
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ing concentrations of ethanol in water [15]. Paraffin embedded
hearts were sectioned to 6–9 mm thickness and stained as
described [15].
Quantitative RT-PCR
Gene expression was measured by quantitative RT-PCR using
the ABI Prism 7700 Sequence Detector (Applied Biosystems) [17].
RNA was isolated from left ventricles of 10-day-old mice using the
ABI Prism 6700 Automated Nucleic Acid Workstation according
to the manufacturer’s protocol. Primers and fluorogenic probes for
b-myosin heavy chain (b-MHC), atrial natriuretic peptide (ANP)
and brain natriuretic peptide (BNP) were described [18]. Levels of
gene expression as a percentage of Ryr2+/+/AC3-C were deter-
mined relative to b-actin.
Preparation of heart homogenates
Hearts of 10-day old mice were homogenized using a Tekmar
Tissumizer for 367 s at a setting of 13,500 rpm in 20 mM
imidazole, pH 7.0, 0.3 M sucrose, 0.15 M NaCl, protease and
phosphatase inhibitor cocktails, 25 mM b-glycerophosphate,
5 mM NaF and 2.5 mM NaVO4. Homogenates were stored in
small aliquots at 280uC. Protein concentrations were determined
using BCA assay.
Immunoblot analyses
Homogenates (20 mg protein/lane) were separated by SDS/
PAGE and transferred to nitrocellulose membranes [19]. Mem-
branes were blotted with 2% Advance blocking reagent (Amer-
sham Biosciences) in 0.5% Tween 20, Tris buffered saline (TBS),
pH 7.4 at 24uC and probed with primary antibodies and
secondary peroxidase-conjugated IgG antibody. Immunoblots
were developed using enhanced chemiluminescence and quanti-
fied using ImageQuantTL Analysis Software.
[3H]Ryanodine binding
Specific binding of [3H]ryanodine to RyRs was measured to
determine the number of RyR high affinity binding sites [20].
Cardiac muscle homogenates were incubated for 4–5 h at 24uC
with a near saturating concentration of 20 nM [3H]ryanodine in
20 mM imidazole, pH 7.0, 0.6 M KCl, 0.1 mM Ca2+, and
protease inhibitors as described [15]. Nonspecific binding was
determined using 1000-fold excess of unlabeled ryanodine.
45Ca2+ uptake rate
ATP-dependent 45Ca2+ uptake rates by homogenates were
determined using a filtration assay as described [15]. 45Ca2+
uptake rates were determined in presence of 6 mM KN93, a
CaMKII specific inhibitor.
Figure 3. Morphological analysis of wild type and mutant hearts. (A) Representative sections of hearts from the indicated mice stained with
hematoxylin and eosin. (B) Left ventricle sections were stained with TRITC-conjugated wheat germ agglutinin. Cross-sectional areas (mm2, n = 10 for
each heart) were (in parentheses) for 2 Ryr2+/+/AC3-C (67.962.3), 3 Ryr2+/+/AC3-I (66.862.8), 4 Ryr2ADA/ADA/AC3-C (96.063.0) and 4 Ryr2ADA/ADA/AC3-I
(86.963.3) hearts. The significantly increased cross-sectional area in Ryr2ADA/ADA hearts compared to Ryr2+/+ hearts was not significantly altered by
AC3-I compared to AC3-C using one way ANOVA. (C) Papillary muscle stained with Masson Trichrome. Arrows indicate collagen deposits.
doi:10.1371/journal.pone.0104338.g003
Ryr2ADA/ADA Mice and AC3 Peptides
PLOS ONE | www.plosone.org 4 August 2014 | Volume 9 | Issue 8 | e104338
Data analysis
Results are expressed as mean 6 SEM. Differences between
samples were analyzed using one or two way ANOVA followed by
Tukey test.
Results
Ryr2+/ADA mutant mice expressing the CaMKII inhibitory
peptide AC3-I or control peptide AC3-C were mated to obtain
Ryr2+/+ and Ryr2ADA/ADA mice expressing AC3-I or AC3-C.
Sixteen Ryr2ADA/ADA mice expressing AC3-I died 12 to 58 days
after birth compared with 16 mutant mice expressing the control
peptide that died 14 to 35 days after birth (Fig. 1). Mean lifetimes
were 28.163.0 and 26.461.6 days for Ryr2ADA/ADA mice
expressing the inhibitory and control peptides, respectively. Thus,
no marked difference in life span occurred between the two
groups.
The effects of expressing AC3-I and AC3-C in Ryr2+/+ and
Ryr2ADA/ADA mice were examined further at day 10 after birth.
Expression of the AC3-I inhibitory peptide did not suppress an
increase in left ventricular weight-to-body weight ratio of Ryr2ADA/ADA
mice compared with mutant mice expressing the AC3-C control
peptide (Table 1). Left ventricle function of 10-day old Ryr2+/+ and
Ryr2ADA/ADA mice expressing AC3-I or AC3-C was compared by
conscious M-mode echocardiography. Heart rates of Ryr2ADA/ADA
mice expressing AC3-I or AC3-C peptide of 477 and 484 beats per
min (bpm) were significantly slower than the 612 and 613 bpm for
Ryr2+/+ mice expressing either of the two peptides (Table 1). Left
ventricular end-diastolic (LVEDD) and end-systolic dimensions
(LVESD) were significantly increased in Ryr2ADA/ADA mice compared
with Ryr2+/+ mice in the absence of the peptides (Fig. 2, Table 1).
Fractional shortening (FS) calculated from the two above parameters
and ejection fraction (EF) were significantly reduced in mutant mice.
However, there was no significant difference between wild-type or
mutant mice expressing AC3-C or AC3-I (Table 1). The data suggest
that inhibition of CaMKII by AC3-I did not improve cardiac
performance of Ryr2ADA/ADA mice compared to mutant mice
expressing the control peptide.
Morphological analysis confirmed the generation of hypertro-
phied hearts and dilated left ventricle chambers in Ryr2ADA/ADA
mice with control or inhibitory peptides (Fig. 3A). Consistent with
left ventricle/body weight ratio (Table 1), there were no noticeable
differences in heart size between AC3-C and AC3-I groups. Heart
sections from 5 wild-type and 8 mutant mice expressing either
AC3-C or AC3-I were stained with TRITC-conjugated wheat
germ agglutinin and cellular cross-sectional areas were deter-
mined. Cross-sectional areas in Ryr2ADA/ADA hearts were signif-
icantly increased compared to Ryr2+/+ hearts (Fig. 3B). However,
there was no significant difference between wild-type or mutant
mice expressing AC3-C or AC3-I. Masson Trichrome staining
indicated negligible collagen deposition in the papillary muscle of
wild-type mice. Ryr2ADA/ADA mice showed an occasional appear-
ance of collagen (Fig. 3C, arrows). However, no obvious
differences were observed between Ryr2+/+ or Ryr2ADA/ADA mice
expressing AC3-C or AC3-I.
Ryr2ADA/ADA mice are germline knock-in mice. While changes
in other tissues cannot be ruled out, the RyR2 mutation appeared
to primarily affect the heart, because body weight ratios were
unchanged for lung, liver and brain.
Immunoblot analysis showed that similar CaMKII protein
levels were present in heart homogenates of wild-type and mutant
mice expressing AC3-C or AC3-I peptides (Figs. 4A and B). We
Figure 4. Expression of CaMKII and pCaMKII-T286 in heart
homogenates. (A) Immunoblots of CaMKII and pCaMKII-T286 of heart
homogenates from 10-day old Ryr2+/+/AC3-C (WC) and/AC3-I (WI) and
Ryr2ADA/ADA/AC3-C (HC) and/AC3-I (HI) mice. Glyceraldehyde-3 phos-
phate dehydrogenase was the loading control. (B) Protein levels of
CaMKII normalized to Ryr2+/+/AC3-C. (C) pCaMKII/CaMKII on Thr-286.
Data were obtained analyzing proteins from 4–6 hearts of each
genotype and are the mean 6 SEM of 15–16 (B) and 5–7 (C)
determinations using two way ANOVA. None of the differences were
significant.
doi:10.1371/journal.pone.0104338.g004
Figure 5. RyR2 phosphorylation on Ser-2809 and Ser-2815 in
heart homogenates. (A) Immunoblots of RyR2, pRyR2-S2809 and
pRyR2-S2815 of heart homogenates from 10-day old Ryr2+/+/AC3-C (WC)
and/AC3-I (WI) and Ryr2ADA/ADA/AC3-C (HC) and/AC3-I (HI) mice. Equal
amounts of proteins (20 mg) were loaded on gels. (B) Intensity of RyR2
protein bands normalized for Ryr2+/+/AC3-C protein band intensities. (C
and D) pRyR2/RyR2 on S2809 and S2815, respectively. Data were
obtained analyzing proteins from 4–6 hearts of each genotype and are
the mean 6 SEM of 13 (B), 4 (C) and 5–7 (D) determinations using two
way ANOVA. *p,0.05 compared with WC and WI. #p,0.05 compared
with HC in blot of total RyR2 shown in B.
doi:10.1371/journal.pone.0104338.g005
Ryr2ADA/ADA Mice and AC3 Peptides
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also determined autophosphorylation of CaMKII on Thr-286,
which switches the kinase from a Ca2+/CaM-dependent to Ca2+/
CaM-independent state. In agreement with a previous study [16],
autophosphorylation of CaMKII increased (not significant) in
wild-type and mutant mice expressing AC3-I compared to mice
expressing AC3-C (Figs. 4A and C). However, increased pCaM-
KII-T286/CaMKII ratio was not expected to enhance CaMKII
activity in AC3-I mice, because autophosphorylated CaMKII is
inhibited by AC3-I [16].
To verify that AC3-I inhibited CaMKII activity in AC3-I mice,
phosphorylation levels of RyR2 and phospholamban (PLN) were
determined by immunoblot analysis. RyR2 is phosphorylated at
Ser-2809 by protein kinase A (PKA) and at Ser-2815 by CaMKII
[21,22]. In agreement with previous studies [15], total RyR2
protein expression was reduced by ,60% in homozygous mice
compared to WT expressing inhibitory and control AC3 peptides
(Fig. 5). In hearts expressing the control peptide, increased
pRyR2-S2809/RyR2 and pRyR2-S2815/RyR2 ratios were ob-
served in mutant hearts compared with total RyR2 protein. AC3-I
reduced (not significant) pRyR2-S2815/RyR2 phosphorylation
ratios in wild-type and mutant hearts compared with hearts
expressing the control peptide. One caveat is that we could not
distinguish between mice carrying transgenes of AC3-I and AC3-
C in one allele or both. It is therefore conceivable that in mice
expressing fewer copies, the AC3-I concentration was suboptimal
in inhibiting CaMKII associated with RyR2 [22].
PLN has two physiologically relevant phosphorylation sites, Ser-
16 phosphorylated by PKA and Thr-17 phosphorylated by
CaMKII [5]. Immunoblots in Fig. 6 show similar total PLN
protein levels in Ryr2+/+ and Ryr2ADA/ADA mice harboring AC3-C
or AC3-I peptides. Among PLN, pPLN-S16/PLN and pPLN-
T17/PLN panels a number of significant changes were observed.
Comparable pPLN-T17/PLN phosphorylation ratios were pres-
ent in Ryr2+/+ and Ryr2ADA/ADA hearts expressing the control
peptide. In contrast, phosphorylation ratios of pPLN-T17/PLN
decreased by 75% in Ryr2+/+ hearts compared to an 85% decrease
in Ryr2ADA/ADA hearts expressing the inhibitory peptide. This
suggests that AC3-I inhibited CaMKII activity in Ryr2+/+ and
Ryr2ADA/ADA hearts.
Protein kinase D (PKD) is a member of the CaMK superfamily
[23] and has been reported to be inhibited by AC3-I [14]. Fig. 7
compares protein levels of PKD and phosphorylation of PKD on
Ser-744/Ser-748 and Ser-916 in wild-type and mutant hearts
expressing AC3-I or AC3-C peptides. Similar PKD protein levels
(Fig. 7B) and pPKD/PKD phosphorylation ratios (Figs. 7C and
D) were observed in hearts of wild-type and Ryr2ADA/ADA mice.
Figure 6. PLN phosphorylation on Ser-16 and Thr-17 in heart homogenates. (A) Immunoblots of PLN, pPLN-Ser16 and pPLN-Thr17 of heart
homogenates from 10-day old Ryr2+/+/AC3-C (WC) and/AC3-I (WI) and Ryr2ADA/ADA/AC3-C (HC) and/AC3-I (HI) mice. Glyceraldehyde-3 phosphate
dehydrogenase was the loading control. (B) Intensity of PLN protein bands normalized for Ryr2+/+/AC3-C protein band intensities. (C and D) pPLN/PLN
on Ser-16 and Thr-17, respectively. Data were obtained analyzing proteins from 4–6 hearts of each genotype and are the mean 6 SEM of 19–22 (B),
12 (C) and 11–12 (D) determinations using two way ANOVA. ap,0.05 compared to WC-T17 and HC-T17, bp,0.05 compared to WI-S16, cp,0.05
compared to WC-S16, dp,0.05 compared to WI-PLN, ep,0.05 compared to HI-T17 fp,0.05 compared to HC-S16.
doi:10.1371/journal.pone.0104338.g006
Ryr2ADA/ADA Mice and AC3 Peptides
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We tested whether AC3-I altered the expression of several genes
linked to cardiac hypertrophy. In agreement with our previous
report [15], quantitative RT-PCR showed that mRNA levels of b-
MHC, ANP and BNP increased in the left ventricle of 10-day old
Ryr2ADA/ADA mice compared to Ryr2+/+ mice (Fig. 8). There were
no marked differences in the expression levels of these genes in
Ryr2+/+ mice expressing AC3-I or AC3-C. Similarly, the
expression levels of b-MHC, ANP and BNP were not significantly
altered in Ryr2ADA/ADA mice expressing AC3-I or AC3-C.
We then asked whether AC3-I altered SR Ca2+ handling of
Ryr2+/+ and Ryr2ADA/ADA mice. Bmax values of [
3H]ryanodine
binding, which are a measure of RyR2 protein levels, and 45Ca2+
uptake rates, which reflect SR Ca2+ pump activity, were
determined. The significantly reduced Bmax of [
3H]ryanodine
binding in Ryr2ADA/ADA hearts compared to Ryr2+/+ [15] was not
altered further by AC3-I or AC3-C in Ryr2+/+ and Ryr2ADA/ADA
mice (Fig. 9A). In mutant mice, reduced 45Ca2+ uptake rates
(Fig. 9B) were likely due to decreased SERCA2a protein content.
In heart homogenates of the mutant mice, we measured decreased
SERCA2a protein content (not shown); however, corresponding
experiments with AC3 homogenates have not been done. 45Ca2+
uptake rates were reduced to a level similar in Ryr2ADA/ADA hearts
expressing AC3-C or AC3-I compared to Ryr2+/+ hearts
expressing AC3-I or AC3-C peptides. SR Ca2+ uptake was likely
not reduced by AC3-I because PLN-S16 phosphorylation, which
was less affected by AC3-I compared to PLN-17 (Fig. 6), was
sufficient to mediate a maximal b-agonist-mediated cardiac
response in perfused hearts [24]. To compensate for the lower
AC3-I concentration due to sample dilution, experiments were
done in the presence of CaMKII inhibitor KN93. Taken together,
the results suggest that the CaMKII inhibitory peptide did not
improve depressed cardiac Ca2+ handling of Ryr2ADA/ADA mice.
Discussion
CaMKII and CaM modulate cardiac muscle function by
regulating multiple ion channels and transport systems [2]. We
previously showed the physiological importance of an interaction
between RyR2 and CaM in cardiac muscle by generating mice
expressing mutant RyR2 (RyR2ADA) with disrupted CaM
regulation [15]. Ryr2ADA/ADA mice develop cardiac hypertrophy
by postnatal day 1 and die within 2 weeks after birth. Impaired
CaM regulation of RyR2 resulted in upregulation of ERK/
p90RSK signaling and reduced GSK-3b activity in E16.5 heart
homogenates [19]. Calcineurin A-b and class II HDAC/MEF2
signaling pathways, which have a critical role in pathological
hypertrophy regulated by CaMKII [25], were up-regulated in 1-
day and 10-day old but not E16.5 Ryr2ADA/ADA hearts [19]. In
the present study, pRyR2-S2815 phosphorylation was not
increased in the mutant mice. The result suggests that CaMKII-
mediated RyR2 phosphorylation does not have an essential role in
the Ryr2ADA/ADA phenotype.
Heart failure is a major public health problem without adequate
therapies. Since CaMKII has emerged as a procardiomyopathic
Figure 7. Expression of PKD, pPKD-S744/S748 and pPKD-S916
in heart homogenates. (A) Immunoblots of PKD, pPKD-S744/748 and
pPKD-S916 of heart homogenates from 10-day old Ryr2+/+/AC3-C (WC)
and/AC3-I (WI) and Ryr2ADA/ADA/AC3-C (HC) and/AC3-I (HI) mice.
Glyceraldehyde-3 phosphate dehydrogenase was the loading control.
(B) Intensity of protein PKD bands in RyR2+/+ and RyR2ADA/ADA hearts
normalized for RyR2+/+/AC3-C protein band intensities. (C and D) pPKD/
PKD on S744/748 and S916, respectively. Data were obtained analyzing
proteins from 4–5 hearts of each genotype and are the mean 6 SEM of
13 (B), 13(C) and 12 (D) determinations using two way ANOVA. None of
the differences were significant.
doi:10.1371/journal.pone.0104338.g007
Figure 8. Quantitative RT-PCR of mRNA from mice double-targeted for RyR2ADA and AC3 peptides. RT-PCR analyses were performed
using total RNA from the left ventricle of 10-day old mice. b-MHC, b-myosin heavy chain; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide.
Data are the mean of 7–8 left ventricle samples using one way ANOVA. p,0.05 compared with Ryr2+/+/AC3-C.
doi:10.1371/journal.pone.0104338.g008
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signal [2,26–31], our goal was to determine whether CaMKII
inhibition has a protective role in a severe form of cardiomyopathy
due to impairment of CaM inhibition of RyR2. The effect of
specific inhibition of RyR2 phosphorylation by CaMKII was
shown by deleting the CaMKII S2815 phosphorylation site of
RyR2. Genetic ablation of RyR2-S2815 phosphorylation indicat-
ed that mutant mice were more resistant than wild-type mice
against pacing-induced arrhythmias following transverse aortic
constriction [6], development of heart failure [7], and arrhythmias
following reperfusion of hearts [32].
We mated Ryr2+/ADA mice with transgenic mice that expressed
CaMKII inhibitory peptide AC3-I or the inactive control peptide
AC3-C. AC3-I protected against structural heart disease by
mimicking the conserved sequence of the CaMKII regulatory
domain [16]. These mouse models also provided evidence that
CaMKII regulates atrioventricular nodal conduction [33]. Inhi-
bition of CaMKII by AC3-I reduced the up-regulation of
proinflammatory genes [34] and protected against apoptosis [35]
during myocardial infarction. In an in vitro kinase assay, we found
that wild-type and Ryr2ADA/ADA mice had comparable CaMKII
activity [15]. This previous study was performed using 1-day old
RyR2ADA/ADA homogenates at a very early stage-of-onset of
cardiac hypertrophy. Cardiac hypertrophy rapidly progresses in
Ryr2ADA/ADA mice, becoming severe by day 10 leading to the early
death of the mutant mice. The present in vivo study that addresses
the role of CaMKII in late stage severe cardiac hypertrophy of 10-
day old mutant mice substantiated earlier in vitro results using 1-
day homogenates. CaMKII phosphorylated RyR2 to a similar
extent in wild-type and mutant hearts in late stage severe cardiac
hypertrophy. Inhibition of CaMKII did not significantly alter the
development of cardiac hypertrophy of Ryr2ADA/ADA mice.
CaMKII inhibition resulted in a significant reduction of PLN
phosphorylation at Thr-17 in Ryr2+/+ and Ryr2ADA/ADA hearts
expressing AC3-I.
We generated and characterized a second mutant mouse model
with a single amino acid substitution (L3591D, RyR2D) in the
CaM binding domain [36]. In contrast to Ryr2ADA/ADA mice,
Ryr2D/D mice showed loss of CaM inhibition at diastolic but not
systolic Ca2+, had a normal lifespan, and showed only modest
changes in heart size and function. This suggested that loss of
CaM regulation in Ryr2D/D mice does not have a major impact as
in Ryr2ADA/ADA mice, implying that CaM inhibition of RyR2 at
systolic Ca2+ is necessary for normal cardiac growth and function
[36]. This was an unexpected finding because a ‘‘leaky’’ RyR2 at
diastolic Ca2+, caused by phosphorylation of RyR2 at Ser2815,
has been implicated in cardiomyopathies [29,31,37]. Our results
suggest that CaMKII did not significantly alter the development of
cardiac hypertrophy of Ryr2ADA/ADA mice at either diastolic or
systolic Ca2+.
Protein kinase D (PKD), a member of the CaMK superfamily
[23], has been reported to be inhibited by AC3-I [14]. While a
direct interaction with RyR2 has not been established, PKD, like
CaMKII, phosphorylates class II histone deacetylases, which
triggers their nuclear export, thereby regulating transcription and
promoting cardiac remodeling [14,38,39]. Immunoblots did not
show significant differences in total PKD, pPKD-S744/S748 and
pPKD-S916 protein levels between 10-day old wild-type and
mutant mice expressing AC3 control or inhibitory peptides
(Fig. 7). However, phosphorylation at these sites does not
necessarily reflect PDK activity in mutant and wild-type hearts.
PKD binds diacylglycerol, which is formed by a variety of cellular
stimuli, inducing cellular redistribution of the enzyme, and
potentially altering PKD activity [23,40]. Therefore, physiological
relevance of in vitro measurements is uncertain, using the isolated
form of the enzyme. To our knowledge there are no unique targets
for PKD that could have been used to assess in vivo PKD activity.
In conclusion, the results suggest that CaMKII does not have an
essential role in the rapid development of cardiac hypertrophy and
early death of mutant mice impaired in CaM regulation of RyR2
at diastolic and systolic Ca2+ concentrations. Although RyR2
mutations that impair CaM regulation in cardiac pathologies have
not yet been identified, our studies should help to understand the
role of RyR2 regulation by CaM and CaMKII in cardiac
hypertrophy and heart failure in humans.
Figure 9. Bmax of [
3H]ryanodine binding (A) and 45Ca2+ uptake rates (B) of heart homogenates from 10-day-old mice double-
targeted for RyR2ADA and AC3 peptides. Data were obtained analyzing homogenates from 4 hearts of each genotype and are the mean 6 SEM
of 4 (A) and 6–7 (B) determinations using one way ANOVA. *p,0.05 compared with Ryr2+/+/AC3-C (A, B) and/AC3-I (A).
doi:10.1371/journal.pone.0104338.g009
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